BarryARBoswellRLawEH, et al. Review of the top 5 cardiology studies of 2011-12. Can Pharm J (Ott)2013;146: 213-7.
2.
BarryARBasarabaJEBongJL, et al. Review of the top 5 cardiology studies of 2013-14. Can Pharm J (Ott)2015; 148:349-54.
3.
BarryARBabadagliHEBasarabaJE, et al. Review of the top 5 cardiology studies of 2015-16. Can Pharm J (Ott)2017; 150:380-6.
4.
McNeilJJWolfeRWoodsRL, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. N Engl J Med2018;379:1509-18.
5.
The ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med2018;379:1529-39.
6.
GazianoJMBrotonsCCoppolecchiaR, et al. Use of aspirin to reduce the risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet2018;392:1036-46.
7.
NealBPerkovicVMahaffeyKW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med2017;377:644-57.
8.
EikelboomJWConnollySJBoschJ, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med2017;377:1319-30.
9.
WiviottSDRazIBonacaMP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med2019;380:347-57.
10.
Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ2002;324:71086.
11.
De BerardisGSaccoMStrippoliGF, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ2009;339:b4531.
12.
Antithrombotic Trialists’ Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet2009;373:1849-60.
13.
RajuNSobieraj-TeagueMHirshJO’DonnellMEikelboomJ.Effect of aspirin on mortality in the primary prevention. Am J Med2011;124:621-9.
14.
BellADRoussinACartierR, et al. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines. Can J Cardiol2011;27:S1-S59.
15.
PiepoliMFHoesAWAgewallS, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J2016;37:2315-81.
16.
VandvikPOLincoffAMGoreJM, et al. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest2012;141:e637S-68S.
17.
Diabetes Canada Clinical Practice Guidelines Expert Committee. Cardiovascular protection in people with diabetes. Can J Diabetes2018;42:S162-S169.
18.
WhitlockEPBurdaBUWilliamsSBGuirguis-BlakeJMEvansCV. Bleeding risks with aspirin use for primary prevention in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med2016;164:826-35.
19.
AndreottiFRoccaBHustedS, et al. Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. Eur Heart J2015;36:3238-49.
20.
McNeilJJWoodsRLNelsonMR, et al. Effect of aspirin on disability-free survival in the healthy elderly. N Engl J Med2018;379:1499-508.
21.
McNeilJJNelsonMRWoodsRL, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med2018;379:1519-28.
Diabetes Canada Clinical Practice Guidelines Expert Committee. Pharmacologic glycemic management of type 2 diabetes in adults. Can J Diabetes2018;42:S88-S103.
24.
ZinmanBWannerCLachinJM, et al. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med2015;373:2117-28.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
